Is Trintellix an MAOI, SSRI, or Neither?

Trintellix is not an MAOI. It belongs to a different class of antidepressants entirely, working through a mechanism that is distinct from how MAOIs function. However, Trintellix and MAOIs have a dangerous interaction, which is likely why this question comes up so often.

How Trintellix Actually Works

Trintellix (vortioxetine) is classified as a multimodal serotonergic antidepressant. It works in two ways: it blocks the serotonin transporter (similar to SSRIs like Prozac or Zoloft), and it directly interacts with several serotonin receptors in the brain. Specifically, it activates some receptors that boost serotonin signaling while blocking others that would dampen it. This combination of actions is why it’s called “multimodal” rather than simply an SSRI or SNRI.

One notable feature of Trintellix is its effect on cognitive function. In clinical trials, it was the only antidepressant to show improvement in processing speed, verbal learning, and recall on a standard cognitive test compared to placebo. These cognitive benefits appear to be largely independent of its antidepressant effect, meaning they aren’t just a side effect of feeling less depressed.

How MAOIs Work Differently

MAOIs, or monoamine oxidase inhibitors, take a completely different approach. Instead of targeting serotonin receptors or transporters, they block an enzyme called monoamine oxidase. This enzyme normally breaks down serotonin, dopamine, and norepinephrine in the brain. By disabling that enzyme, MAOIs cause levels of all three chemicals to rise.

Only a handful of MAOIs are FDA-approved for depression:

  • Isocarboxazid (Marplan)
  • Phenelzine (Nardil)
  • Tranylcypromine (Parnate)
  • Selegiline (Emsam), available as a skin patch

Some medications not typically thought of as MAOIs also have MAOI activity, including the antibiotic linezolid and intravenous methylene blue. These carry the same interaction risks.

Why Combining Them Is Dangerous

Because both Trintellix and MAOIs increase serotonin levels in the brain, taking them together can push serotonin dangerously high, triggering a condition called serotonin syndrome. The FDA specifically lists the combination as contraindicated.

Serotonin syndrome can range from mild to life-threatening. Early symptoms include agitation, restlessness, rapid heart rate, high blood pressure, dilated pupils, muscle twitching, heavy sweating, and diarrhea. In severe cases, it can cause high fever, seizures, irregular heartbeat, and unconsciousness. The condition most often occurs when two serotonin-boosting drugs are combined, and the MAOI-plus-serotonergic-antidepressant pairing is one of the highest-risk combinations.

Required Waiting Periods When Switching

If you’re switching between Trintellix and an MAOI in either direction, there are strict waiting periods to let the first medication fully clear your system before starting the second.

If you’re stopping an MAOI and starting Trintellix, you need to wait at least 14 days after your last MAOI dose. This gives the enzyme enough time to regenerate in your brain.

If you’re stopping Trintellix and starting an MAOI, the wait is longer: at least 21 days. Trintellix has an unusually long half-life of roughly 66 hours (about 2.75 days), meaning it takes considerably longer than most antidepressants to leave your body completely. That extended half-life is the reason the washout period going in this direction is three weeks rather than two.

These timelines aren’t flexible suggestions. The FDA prescribing information treats them as hard minimums to avoid the risk of serotonin syndrome. Your prescriber will manage the specific transition schedule if a switch is needed.

Other Drug Classes Trintellix Interacts With

MAOIs aren’t the only concern. Because Trintellix raises serotonin levels, combining it with other serotonergic medications also increases the risk of serotonin syndrome. This includes SSRIs, SNRIs, and tricyclic antidepressants. The risk is lower than with MAOIs, but it still exists, particularly at higher doses or when multiple serotonin-boosting drugs overlap during a medication switch.